Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
In recent years, there has been a wide range of treatment options for patients with metastatic HER2-positive breast cancer, resulting in the highest life expectancy for these patients among all subtypes. The addition of pertuzumab to trastuzumab and docetaxel has been shown to increase overall...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6594 |
| _version_ | 1797842015896993792 |
|---|---|
| author | M. A. Frolova M. B. Stenina |
| author_facet | M. A. Frolova M. B. Stenina |
| author_sort | M. A. Frolova |
| collection | DOAJ |
| description | In recent years, there has been a wide range of treatment options for patients with metastatic HER2-positive breast cancer, resulting in the highest life expectancy for these patients among all subtypes. The addition of pertuzumab to trastuzumab and docetaxel has been shown to increase overall survival and is therefore recognized as the standard first-line treatment. The most optimal second-line treatment option is trastuzumab emtansine. In addition, various combinations of cytostatics and anti HER2 targeting agents can be used. The choice of treatment options in heavily pretreated patients is of great interest. If they have not previously received pertuzumab, is it worth to use it and which combination is the best? One possible option is the combination of eribulin with the dual anti-HER2 blockade with trastuzumab and pertuzumab. Eribulin is an anti-microtubule agent that irreversibly blocks mitosis. In addition, it has non-mitotic effects – in vivo and in vitro experiments demonstrated its ability to restore normal tumor vascularization, reduce the area of hypoxia and, as a consequence, decrease tumor cells migration and invasion. This article represents a clinical case of the use of eribulin with double anti-HER2 blockade in the 6th line of treatment in a patient with metastatic HER2-positive breast cancer. Long-term control of the disease (within 2 years) with a satisfactory quality of life has been demonstrated. |
| first_indexed | 2024-04-09T16:41:08Z |
| format | Article |
| id | doaj.art-1966b5f19b234fa8a3a8fe228bc7064f |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:41:08Z |
| publishDate | 2021-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-1966b5f19b234fa8a3a8fe228bc7064f2023-04-23T06:56:41ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-12-0102015615910.21518/2079-701X-2021-20-156-1595955Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancerM. A. Frolova0M. B. Stenina1Blokhin National Medical Research Center of OncologyBlokhin National Medical Research Center of OncologyIn recent years, there has been a wide range of treatment options for patients with metastatic HER2-positive breast cancer, resulting in the highest life expectancy for these patients among all subtypes. The addition of pertuzumab to trastuzumab and docetaxel has been shown to increase overall survival and is therefore recognized as the standard first-line treatment. The most optimal second-line treatment option is trastuzumab emtansine. In addition, various combinations of cytostatics and anti HER2 targeting agents can be used. The choice of treatment options in heavily pretreated patients is of great interest. If they have not previously received pertuzumab, is it worth to use it and which combination is the best? One possible option is the combination of eribulin with the dual anti-HER2 blockade with trastuzumab and pertuzumab. Eribulin is an anti-microtubule agent that irreversibly blocks mitosis. In addition, it has non-mitotic effects – in vivo and in vitro experiments demonstrated its ability to restore normal tumor vascularization, reduce the area of hypoxia and, as a consequence, decrease tumor cells migration and invasion. This article represents a clinical case of the use of eribulin with double anti-HER2 blockade in the 6th line of treatment in a patient with metastatic HER2-positive breast cancer. Long-term control of the disease (within 2 years) with a satisfactory quality of life has been demonstrated.https://www.med-sovet.pro/jour/article/view/6594her2-positive metastatic breast cancerdouble anti-her2 blockadetrastuzumabpertuzumaberibulin |
| spellingShingle | M. A. Frolova M. B. Stenina Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer Медицинский совет her2-positive metastatic breast cancer double anti-her2 blockade trastuzumab pertuzumab eribulin |
| title | Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer |
| title_full | Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer |
| title_fullStr | Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer |
| title_full_unstemmed | Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer |
| title_short | Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer |
| title_sort | dual anti her2 blockade in late line treatment of metastatic her2 positive breast cancer |
| topic | her2-positive metastatic breast cancer double anti-her2 blockade trastuzumab pertuzumab eribulin |
| url | https://www.med-sovet.pro/jour/article/view/6594 |
| work_keys_str_mv | AT mafrolova dualantiher2blockadeinlatelinetreatmentofmetastaticher2positivebreastcancer AT mbstenina dualantiher2blockadeinlatelinetreatmentofmetastaticher2positivebreastcancer |